Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Conference Call February 15, 2024 5:00 PM ET Company Participants Atabak Mokari - ...
Sunday, January 5, 2025
Tag: Therapeutics
Stifel raises Viking Therapeutics price target citing strong portfolio By Investing.com
© Reuters. On Wednesday, Stifel, a financial services firm, raised its price target for Viking Therapeutics (NASDAQ:) to $35 from ...
4D Molecular Therapeutics launches $250M stock offering By Investing.com
© Reuters. EMERYVILLE, Calif. - 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage genetic medicines company, announced today that it has ...
Dyne Therapeutics prices stock offering to raise $300.1 million
Dyne Therapeutics (NASDAQ:DYN) announces the pricing of an underwritten public offering of 17.15 million shares of its common stock at ...
Corcept Therapeutics stock plunges after loss in patent battle with with Teva
Dr_Microbe/iStock via Getty Images Corcept Therapeutics (NASDAQ:CORT) plummeted 38% in after-hours trading on Friday after a loss in a patent ...
Incannex: Recently U.S.-Domiciled Developer Of Cannabinoid Therapeutics (NASDAQ:IXHL)
Michael Fischer Incannex Healthcare Inc. (NASDAQ:IXHL) is a developer of medicinal cannabinoid and psychedelic pharmaceutical product candidates. The company was ...
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - ...
CytomX Therapeutics Reports Q3 2023 Results, Highlights Pipeline Progress and Strategic Partnerships By Investing.com
© Reuters. CytomX Therapeutics (NASDAQ:), a company dedicated to the discovery and development of novel cancer medicines, has reported its ...
Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Vivian Wu - Director, ...
Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B
Drew Angerer/Getty Images News Bristol-Myers Squibb (NYSE:BMY) agreed to purchase cancer drug maker Mirati Therapeutics (NASDAQ:MRTX) for about $4.8 billion. ...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.